Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Pain Symptom Manage. 2018 Nov 23;57(3):596–606. doi: 10.1016/j.jpainsymman.2018.11.015

Table 4.

Associations of Symptom Cluster with Survivors’ Breast Cancer-Specific QOL

FACT-BCS
Effect β SE
Intercept 23.90*** 3.02
Group - High Symptom (vs. low) −6.74*** 0.72
Time - 12 month 0.43 0.36
Time - 24 month 1.07** 0.39
GroupXTime - High Symptom, 12 month 3.53*** 0.97
GroupXTime - High Symptom, 24 month 3.15** 1.05
Age 0.10* 0.04
Race - other race −0.25 0.59
Cognitive Reserve (WRAT score) 0.00 0.02
Comorbidity −0.58*** 0.13
APOE - ε4 positive 0.75 0.57
Stage - Stage 2–3 −0.52 0.51
Treatment - Hormone only 0.07 0.55
*

p<0.05

**

p<0.01

***

p<0.001

Reference groups: low symptom for group, baseline for time, White for race, ε4 negative for APOE, stage 0–1 for stage, chemotherapy with or without hormone therapy for treatment. The model also controlled for study site. Estimates for each group by time interaction represent the average difference in rate of change for the high symptom group relative to the low symptom group after adjusting for covariates.